表 2.
两组患者的实验室检查差异
Laboratory differences between the two groups
| Variable | Retinopathy group (n=50) | Non-retinopathy group (n=50) | t/U | P |
| Hb, hemoglobin; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; Alb, albumin; 24h-UTP, twenty-four hours urine total protein; ANA, antinuclear antibody; dsDNA, double stranded deoxyribonucleic acid; Sm, Smith; RNP, ribonucleoprotein; SSA, Sjögren’s syndrome related antigen A; SSB, Sjögren’s syndrome related antigen B; AnuA, Anti-nucleosome antibodies; ACLA, anticardiolipin antibody; β2 GP 1, β2 glycoprotein 1 antibody; LAC, lupus anticoagulant; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM immunoglobulin M; C3, complement 3; C4, complement 4. *P < 0.05. # P < 0.001. a, Fisher’s exact test. | ||||
| Hb/(g/L), x±s | 91.64±25.18 | 113.96±18.57 | 4.838 | < 0.001# |
| ESR/(mm/h), M (P25, P75) | 42.00 (24.00, 64.50) | 18.50 (7.00, 34.25) | 583.5 | < 0.001# |
| CRP/(mg/L), M (P25, P75) | 2.91 (1.61, 6.76) | 1.41 (0.56, 6.89) | 654.0 | 0.019* |
| Alb/(g/L), x±s | 30.78±6.70 | 33.05±7.61 | 1.517 | 0.133 |
| 24 h-UTP/(g/d), M (P25, P75) | 0.64 (0.22, 1.87) | 0.19 (0.10, 1.44) | 700.0 | 0.026* |
| ANA (+), n (%) | 46 (92.0) | 45 (90.0) | 0.000 | 1.000a |
| Anti-dsDNA (+), n (%) | 31 (62.0) | 30 (60.0) | 0.042 | 0.838 |
| Anti-dsDNA/(IU/mL), M (P25, P75) | 113.30 (29.80, 200.00) | 49.60 (19.68, 200.00) | 735.0 | 0.146 |
| Anti-Sm antibody (+), n (%) | 10 (20.0) | 9 (18.0) | 0.065 | 0.799 |
| Anti-RNP antibody (+), n (%) | 19 (38.0) | 20 (40.0) | 0.042 | 0.838 |
| Anti-SSA antibody (+), n (%) | 21 (42.0) | 27 (54.0) | 1.442 | 0.230 |
| Anti-SSB antibody (+), n (%) | 6 (12.0) | 5 (10.0) | 0.102 | 0.749 |
| AnuA (+), n (%) | 29(58.0) | 24 (48.0) | 1.004 | 0.316 |
| AnuA/(RU/mL), M (P25, P75) | 44.68 (8.23, 151.43) | 22.63 (9.40, 186.42) | 881.0 | 0.736 |
| ACLA (+), n (%) | 15 (30.0) | 6 (12.0) | 4.882 | 0.027* |
| ACLA/(U/mL), M (P25, P75) | 4.60 (2.00, 11.40) | 3.50 (2.15, 7.28) | 878.5 | 0.364 |
| Anti-β2 GP 1 (+), n (%) | 15 (30.0) | 10 (20.0) | 1.477 | 0.224 |
| Anti-β2 GP 1/(RU/mL), M (P25, P75) | 6.72 (2.08, 37.14) | 7.47 (2.83, 14.61) | 931.5 | 0.773 |
| LAC (+), n (%) | 9 (18.0) | 3 (6.0) | 2.367 | 0.121a |
| LAC/s, M (P25, P75) | 1.02 (0.95, 1.37) | 0.99 (0.93, 1.13) | 693.0 | 0.251 |
| Coombs test (+), n (%) | 29 (58.0) | 20 (40.0) | 7.241 | 0.072 |
| IgA (g/L), x±s | 2.42±1.28 | 2.88±1.28 | 1.671 | 0.098 |
| IgG/(g/L), M (P25, P75) | 13.50 (10.25, 20.30) | 13.90 (8.80, 19.00) | 921.5 | 0.463 |
| IgM/(g/L), M (P25, P75) | 1.09 (0.56, 1.66) | 0.90 (0.47, 1.36) | 798.5 | 0.213 |
| C3/(g/L), M (P25, P75) | 0.41 (0.253, 0.627) | 0.59 (0.385, 0.712) | 704.5 | 0.006* |
| C4/(g/L), M (P25, P75) | 0.05 (0.025, 0.130) | 0.12 (0.046, 0.157) | 755.5 | 0.018* |